Q1 2025 Schrodinger Inc Earnings Call Transcript
Key Points
- Schrodinger Inc (SDGR) reported a strong Q1 2025 with total revenue of $59.6 million, a 63% increase compared to Q1 2024.
- Software revenue grew by 46% to $48.8 million, driven by larger customer renewals and expansions of multiyear contracts.
- Drug discovery revenue increased significantly to $10.7 million, bolstered by milestones from collaborative programs and upfront revenue from the Novartis collaboration.
- The company is advancing its predictive toxicology initiative, with plans for a beta release to select customers later this year.
- Schrodinger Inc (SDGR) maintains a strong financial position with a cash balance increase to $512 million, supported by collections from contracts and upfront payments.
- Professional services revenue declined by 31% due to the completion of service contracts from prior periods.
- The software gross margin decreased to 72% from 76% in Q1 2024, impacted by the revenue mix associated with the Gates grant.
- Drug discovery cost of revenue increased, driven by high costs associated with the Novartis collaboration and increased research staff allocation.
- The company reported a net loss after taxes of $60 million, or $0.82 per share, compared to a net loss of $54.7 million in Q1 2024.
- There was a loss of $13 million in the change in fair value of equity method investments, compared to a gain of $8 million in Q1 2024.
Thank you for standing by. Welcome to Schrödinger's conference call to review first-quarter 2025 financial results. My name is Kelvin, and I will be your operator for today's call. Please be advised that this call is being recorded at the company's request.
Now, I would like to introduce your host for today's conference, Ms. Jarren Madden, Senior Vice President of Investor Relations and Corporate Affairs. Please go ahead.
Thank you, and good afternoon, everyone. Welcome to today's call, during which we will provide an update on the company and review our first-quarter 2025 financial results. Earlier today, we issued a press release summarizing our financial results and progress across the company, which is available on our website at schwinger.com. Here on our call today are Ramy Farid, Chief Executive Officer; Geoff Porges, Chief Financial Officer; and Karen Akinsanya, President of R&D Therapeutics. Following our prepared remarks, we'll open the call
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
